A Cohort Study on Milk Composition, Health Outcomes, and Feeding Practices of Chinese Mothers and Infants (Phoenix)

March 1, 2023 updated by: Danone Nutricia
This is a cohort study to understand the changes of breastmilk composition in the first six months after birth of Chinese infants.

Study Overview

Detailed Description

The relationship of breastmilk composition, the maternal gut microbiome and lifestyle factors such as diet, feeding practices and physical activity and the infant's health and gut microbiome will be investigated in this study.

Study Type

Observational

Enrollment (Anticipated)

750

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 211166
        • Recruiting
        • Nanjing Medical University Jiangning Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Generally healthy mothers with the intention to breastfeed, and their infants.

Description

Inclusion Criteria:

Mothers:

  1. Generally healthy mothers with the intention to breastfeed.
  2. Aged 18 years and above.
  3. Written informed consent.

Infants:

  1. Generally healthy term born (gestational age between 37 and 42 weeks).
  2. Breastfed by their mothers, either exclusively or in combination with infant milk formula, at enrolment.
  3. Chinese ethnicity of mother and father.

Exclusion Criteria:

Mothers:

  1. Participation in any other studies involving investigational or marketed products concomitantly or two weeks prior to entry into the study.
  2. Difficulty to follow up and/or locate (e.g. known transfer to other hospitals, residing outside the city where the study site is located, or planning to move out of the current city; incapability of mothers to comply with study protocol or investigator' s uncertainty about the willingness or ability of the mothers to understand and comply with the protocol requirements.
  3. Illegal drug use.
  4. Regular smoking and/ or consumption of alcoholic beverages as per investigator's judgement.
  5. A BMI of <18.5 or ≥ 28 pre-pregnancy or during the first regular pregnancy check around or before 16 weeks of gestational age.
  6. Acute infectious disease or neoplastic disease or any kind of weakening or debilitating conditions (with history of positive, hepatitis C virus (HCV) or HIV serological test at any time during the pregnancy).
  7. Presence of mastitis, fungal infections of the nipple or areola; reactivation of herpes simplex (HSV) or varicella zoster infection in the mammary or thoracic region at the time of enrolment.
  8. Presence of chronic diseases such as endocrine, cardiovascular, renal, respiratory or hepatic diseases.
  9. Presence of psychosis and severe post-partum depression.
  10. Presence of autoimmune disease such as systemic lupus erythematosus, systemic scleroderma, ulcerative colitis, Crohn's disease, celiac disease.
  11. Women whose health condition, according to the investigator's judgement, could interfere with the study conduction and assessment.
  12. Mothers who have given birth to twins or multiples or infant conceived with Assisted Reproductive Technology (ART).

Infants:

  1. Participation in any other studies involving investigational or marketed products concomitantly or two weeks prior to entry into the study.
  2. At enrolment, any congenital abnormality, chromosomal disorder or severe disease which could interfere with the study conduct and assessment.
  3. Consumption of food other than breast milk or infant formula.
  4. Fully formula fed at enrolment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chinese mothers with the intention to breastfeed, and their infants.
Observational study.
Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in human milk protein concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Protein concentration in g/l of human milk will be analyzed
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in human milk fat concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Fat concentration in g/l of human milk will be analyzed
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in human milk carbohydrate concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Carbohydrate concentration in g/l of human milk will be analyzed
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in human milk energy content
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Energy content in kCal/l of human milk will be analyzed
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in infant length
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
Length measured in cm
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
Changes in infant head circumference
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
Head circumference measured in cm
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
Changes in infant weight
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
Weight measured in grams
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variations in human milk microbiome
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by sequencing
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in human milk micronutrients
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by mass spectrometry
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in human milk oligosaccharides (HMOs)
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by mass spectrometry
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in human milk lipid composition
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by mass spectrometry
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in human milk amino acids and proteins
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by mass spectrometry
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in infant fecal microbiome
Time Frame: Infant fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by sequencing
Infant fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Variations in maternal fecal microbiome
Time Frame: Maternal fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Analyzed by sequencing
Maternal fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in infant stool consistency and frequency
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
Data will be collected via diaries using the Brussel Infant and Toddler Stool Scale
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in infant feeding practices
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
Dietary data will be collected via questionnaires
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
Changes in maternal body mass index
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
Maternal weight and height will be combined to determine body mass index [kg/m2]
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 19, 2021

Primary Completion (Anticipated)

November 30, 2024

Study Completion (Anticipated)

March 30, 2025

Study Registration Dates

First Submitted

December 10, 2021

First Submitted That Met QC Criteria

February 8, 2022

First Posted (Actual)

February 11, 2022

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • SBB20R&32016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Feeding

Clinical Trials on Not applicable: Observational study without any interventions.

3
Subscribe